Latest Form 4 insider transactions

Kelly L Palumbo, SVP, Controller and CAO of CAMPBELL'S Co, received 16,161 shares of common stock on October 1, 2026.

Julie Jarecke Gebauer, Pres.-Health, Wealth & Career of Willis Towers Watson Plc, reported multiple transactions in common stock on October 9, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 2,977 shares of common stock on October 9, 2026.

Ryan Cohen, President, CEO and Chairman and a Director of GameStop Corp., purchased 844,130 shares of common stock on October 13, 2026.

Julius Genachowski, a Director of Mastercard Inc, sold 741 shares of common stock on October 9, 2026.

Sarah Kaplan Browne, Chief Medical Officer of MetaVia Inc., received 53,000 shares of common stock on October 12, 2026.

Karl Alexander Vollert, a Director of State Street Corp, received 784 shares of common stock on October 9, 2026.

Marc Boroditsky, Chief Revenue Officer of Nebius Group N.V., sold 7,000 shares of common stock on October 12, 2026 for $211.23 per share.

Melissa Nippert, SVP, Chief Transformation Ofcr of CAMPBELL'S Co, received 19,709 shares of common stock on October 1, 2026.

Carl Aaron Hess, Chief Executive Officer and a Director of Willis Towers Watson Plc, reported multiple transactions in common stock on October 9, 2026.

Quantumsphere Acquisition Corporation has entered into a definitive agreement to merge with Fortune Favor Technology Inc., a company specializing in medical cold-chain transportation solutions.

Phillip Goldstein, Secretary and a Director of Swiss Helvetia Fund, Inc., purchased 5,000 shares of common stock on October 1, 2026 for $5.73 per share.

Daniel Gazit, Chief Product Officer of Kornit Digital Ltd., sold 552 shares of common stock on October 9, 2026 for $19.01 per share.

Pierre Sargis Sayad, Chief Medical Officer of Fennec Pharmaceuticals Inc., received 3,846 shares of common stock on October 12, 2026.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 1,249 shares of common stock on October 9, 2026.

Hongfei Huang, Chief Financial Officer of Chagee Holdings Ltd., received 675,464 shares of common stock on October 12, 2026.

Jeffrey S. Hackman, Chief Executive Officer and a Director of Fennec Pharmaceuticals Inc., received 2,224 shares of common stock on October 12, 2026.

Adam Laponis, Chief Financial Officer of Twist Bioscience Corp, sold 2,462 shares of common stock on October 9, 2026 for $156.30 per share.

Terry L Evans, Chief Commercial Officer of Fennec Pharmaceuticals Inc., received 2,326 shares of common stock on October 12, 2026.

Andrew Jay Krasner, Chief Financial Officer of Willis Towers Watson Plc, reported multiple transactions in common stock on October 9, 2026.

Christiana Marie Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals Inc., received 3,946 shares of common stock on October 12, 2026.

Robert Andrade, CHIEF FINANCIAL OFFICER of Fennec Pharmaceuticals Inc., received 3,846 shares of common stock on October 12, 2026.

PlusAI and Texas Ventures Acquisition III Corp have filed a registration statement on Form S-4, a key milestone for their proposed business combination and PlusAI's public listing.

Leonardo Pareja, CEO of EXP World Holdings, Inc., received 573,588 shares of common stock on October 12, 2026.

Joseph Stephen Kurpis, PAO and Controller of Willis Towers Watson Plc, received 31 shares of common stock on October 9, 2026.

Anne Pullum, Co-Head of Corporate Dev. of Willis Towers Watson Plc, reported multiple transactions in common stock on October 9, 2026.

Imran Ahmed Qureshi, Global Head of Geographies of Willis Towers Watson Plc, reported multiple transactions in common stock on October 9, 2026.

Robert Christopher Bissell, a 10% owner of QumulusAI, Inc., reported a transaction in 15,000 shares of common stock on October 9, 2026.

Daniel W. Fleming, Chief Financial Officer of Credo Technology Group Holding Ltd, sold 7,580 shares of common stock on October 8, 2026.

Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on October 12, 2026 for $62.88 per share.